Report of proceedings of the national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry"

Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital

“…2006 Bethesda international consensus guidelines define an extensive reagent panel suitable for both AL and MBNHL [57]. Indian Guidelines, however, recommend a minimal primary panel for evaluating mature lymphoid neoplasms including CD19, CD5, CD23, CD10, FMC7, CD20, CD3, kappa and lambda [58] followed by a more comprehensive panel, if required, including CD38, CD138, CD43, CD56, CD16, CD11c, CD25 and CD103. This panel hopefully brings about uniformity and comparability in reporting of hematolymphoid malignancies and bridges the divide between low-cost reporting and an accurate diagnosis.…”

CD8 expression in B chronic lymphocytic leukemia: A case of immuno‐phenotypic aberrancy

“…The panels are B cell centric and gating using CD19/CD3 is as per individual's choice. The primary panels have been selected to on the basis of diagnostic efficacy matched with cost effective strategy . We in our lab use additional T cell markers CD7, CD4, CD8 in each CLPD case.…”

Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification

“…A three-or 4-color flow cytometer is good enough for routine diagnostic work-up, although there are some centers using 9-to 10-color flow cytometers (Kussick SJ & Wood BL, 2003;Wood BL, 2006). Various panels have been recommended according to the type of flow cytometer, regional requirements, available resources, and personal preferences (Bene MC et al, 1995;Gujral S et al, 2008;Nguyen D et al, 2003). There is no universal consensus on the panel design.…”